Dendreon stock rose Friday after the drug developer said a European Medicines Agency committee endorsed its prostate cancer treatment, a drug approved for use in the United States more than three years ago.
Shares of Dendreon closed up 4 cents, or 1 percent, to $4.12, after earlier climbing as high a $4.49.
The Seattle company said the agency’s Committee for Medicinal Products for Human Use gave a positive opinion recommending that Provenge be approved for sale in the European Union.
The European Commission, which approves medicines for the EU, usually makes a decision on these recommendations in a few months.
Most Read Business Stories
- Boeing 747 engine catches fire, drops parts over the Netherlands, injuring 2
- Boeing 757 bound for Seattle makes emergency landing
- Seattle among top markets as U.S. home prices increase by double-digit percentages for the first time in years
- Will downtown Seattle bounce back after the pandemic?
- Another top Amazon executive to leave company
Provenge is approved in the United States for men whose cancer has spread elsewhere in the body and has not responded to hormone therapy or radiation. It is designed to train a patient’s immune system to fight prostate cancer.
Dendreon said last month that net revenue from Provenge fell 18 percent to $67.6 million in the first quarter due to increased competition from two newer drugs. Analysts initially expected billions of dollars per year in annual sales. Sales have been hurt by the drug’s high cost and because some doctors are not convinced that it extends patients’ lives a great deal compared with chemotherapy.